We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov Menu

Study of Two Formulations of Buprenorphine HCl in Opioid-dependent Subjects on Buprenorphine Maintenance Therapy (Study P04451) (COMPLETED)

This study has been completed.
ClinicalTrials.gov Identifier:
First Posted: February 25, 2010
Last Update Posted: April 19, 2011
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Reckitt Benckiser LLC
Information provided by:
Indivior Inc.

This is a multi-center, open-label, preference study of two sublingual formulations of buprenorphine HCl, in opioid-dependent patients on buprenorphine maintenance therapy.

The objectives of this study are to evaluate the overall preference between two buprenorphine sublingual formulations, after a switch from the marketed tablet (Subutex®) to the new fast dissolving tablet (FDT), in opioid-dependent patients with buprenorphine 8 mg or 16 mg daily maintenance therapy.

Condition Intervention Phase
Opioid Dependency Drug: Buprenorphine hydrochloride marketed sublingual tablet (Subutex) Drug: Buprenorphine hydrochloride fast dissolving tablet (FDT) Phase 2

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Evaluation of Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine Maintenance Therapy

Resource links provided by NLM:

Further study details as provided by Indivior Inc.:

Primary Outcome Measures:
  • The Overall Preference Between Two Buprenorphine Sublingual Formulations, After a Switch From the Marketed Tablet (Subutex®) to the New Fast Dissolving Tablet (FDT), in Opioid-dependent Patients With Buprenorphine 8 mg or 16 mg Daily Maintenance Therapy. [ Time Frame: Daily, Day 1 to Day 5 ]
    Patient's overall satisfaction on Day 1 to Day 5 postdose. Marketed sublingual tablet (Marketed SL): Days 1 and 2; Fast dissolving tablet (FTD): Days 3, 4, and 5. Within 1 hour after complete dissolution of the tablet(s), overall satisfaction towards the study treatment was to be scored by the patient himself / herself using a 10-cm visual analogic scale (VAS) ranging from "Not at all satisfied" (score = 0) to "Totally satisfied" (score = 10).

Enrollment: 52
Study Start Date: September 2005
Study Completion Date: November 2005
Primary Completion Date: November 2005 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Buprenorphine hydrochloride Drug: Buprenorphine hydrochloride marketed sublingual tablet (Subutex)
8 mg or 16 mg daily, sublingual route on Days 1 and 2
Other Name: Subutex®
Drug: Buprenorphine hydrochloride fast dissolving tablet (FDT)
8 mg or 16 mg daily, sublingual route on Days 3, 4, and 5


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients must demonstrate their willingness to participate in the study and comply with its procedures by signing a written informed consent.
  • Patients must be at least (≥) 18 years of age, of either sex.
  • Patients treated for opioid dependence with Subutex®, with a stable dosage of 8 mg or 16 mg daily, and respecting the legal drug attachments.
  • Patients must understand and be able to adhere to the dosing and visit schedules, and agree to report concomitant medications / products and adverse events to the investigator or designee.
  • Women of childbearing potential (includes women who are less than one year postmenopausal and women who become sexually active) must be using or agree to use an acceptable method of birth control (e.g., hormonal contraceptive, medically prescribed IUD, condom in combination with spermicide) or be surgically sterile (e.g., hysterectomy or tubal ligation).
  • Women of childbearing potential should be counseled in the appropriate use of birth control while in this study. Women who are not currently sexually active must agree and consent to use one of the above-mentioned methods should they become sexually active while participating in the study.
  • Women of childbearing potential must have a urine pregnancy test with negative result within 2 weeks prior to inclusion (as performed under control of the investigator or designee).

Exclusion Criteria:

  • Patients refusing to take the daily dose of the study medication under control in the center.
  • Patients unable to complete the evaluations.
  • Women who are pregnant or nursing.
  • Patients with a history of hypersensitivity to buprenorphine hydrochloride or any excipient of one of its formulations.
  • Patients with a current evidence of alcohol abuse.
  • Patients with severe respiratory dysfunction, severe hepatic dysfunction, acute alcohol intoxication or delirium tremens.
  • Initiation or increase in the dose, within the past 7 days or scheduled during the study, of a treatment with:

    • benzodiazepines,
    • other depressants of the central nervous system: other morphine derivatives (analgesics, antitussives), certain antidepressive agents, sedative H1 antihistamines, barbiturates, benzodiazepines, anxiolytics other than benzodiazepines, neuroleptics, clonidine and clonidine-like agents,
    • monoamine oxydase [MAO] inhibitors.
  • Patients who have any current evidence of clinically significant hematopoietic, metabolic, cardiovascular, immunologic, neurologic, hematological, gastrointestinal, hepatic, renal, psychiatric, cerebrovascular, or respiratory disease, or any other disorder which, in the judgment of the investigator, may interfere with the study evaluations or affect patient safety.
  • Patients who have used any investigational product within 30 days prior to enrollment.
  • Patients participating in another trial at the same time.
  • Patients intending to donate blood during the study or within 3 months after study completion.
  • Patients in the exclusion period of the "Fichier National des personnes qui se prêtent à des recherches biomédicales sans bénéfice individuel direct" (National Index of persons participating in biomedical researches without direct individual benefit, or National Index of volunteers).
  • Patients without Social Security number, or whose maximum annual compensation (3,800 €) has been exceeded.
  Contacts and Locations
No Contacts or Locations Provided
  More Information

Responsible Party: Head, Clinical Trials Registry & Results Disclosure Group, Schering-Plough
ClinicalTrials.gov Identifier: NCT01075971     History of Changes
Other Study ID Numbers: P04451
First Submitted: February 24, 2010
First Posted: February 25, 2010
Results First Submitted: March 26, 2010
Results First Posted: April 13, 2010
Last Update Posted: April 19, 2011
Last Verified: April 2010

Keywords provided by Indivior Inc.:
Buprenorphine tablet
Fast dissolving tablet
Opioid dependant patients

Additional relevant MeSH terms:
Analgesics, Opioid
Central Nervous System Depressants
Physiological Effects of Drugs
Sensory System Agents
Peripheral Nervous System Agents
Narcotic Antagonists